MAR 23, 2019 09:13 PM PDT

New Drug Therapeutic for Portal Hypertension

WRITTEN BY: Nouran Amin

According to a study published in the journal of the American Gastroenterological Association, drug therapy, called sivelestat, may effectively treat life-threatening liver diseases such as those associated with cirrhosis and in particular lower portal hypertension.

Results of the study concluded by Mayo Clinic researchers have showed that sivelestat, in mouse models and human liver samples, improved symptoms and outcomes for liver disease patients. "This was an exciting confirmation of our findings and their applicability to human disease" says, Dr. Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author. "Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease."

Current therapeutics are available for certain forms of liver disease, such as hepatitis C and autoimmune hepatitis, however treatments have been limited for treating portal hypertension--a condition associated with cirrhosis and other chronic liver diseases and characterized by an increase in pressure within the portal vein that carries blood from abdominal organs to the liver.

"The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces," says Dr. Moira Hilscher M.D., the paper's first author. "Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need."

Specifically, the study showed that sivelestat decreases portal hypertension through the inhibition of the neutrophil function. Neutrophils are critical cells of the immune system that are involved in producing microvascular blood clots known as fibrin which in turn contributes portal hypertension. "Neutrophils had not previously been identified as significant drivers of portal hypertension," says Hilscher.

Results of the study were illustrated in two models of chronic liver disease.

Source: Mayo Clinic

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 17, 2018
Drug Discovery
DEC 17, 2018
Nanocapsules Improve The Delivery of Antiparasitic Drugs
The efficacy of antiparasitic medications highly depends on how they dissolve and are absorbed by the body—limiting the therapeutic potential of trad...
DEC 27, 2018
Cannabis Sciences
DEC 27, 2018
Parents Turning to Medical Marijuana to Treat Children's Autism
WHEC News in Rochester, New York, is reporting that more adults are turning to medical marijuana to treat their child's autism. The parents claim that...
FEB 25, 2019
Drug Discovery
FEB 25, 2019
Photoelectrochemical Cells To Produce New Drug Discovery Molecules
Photoelectrochemical (PEC) cells utilize photocathodes and photoanodes to "split" water into hydrogen and oxygen. PEC cells have been primarily s...
FEB 27, 2019
Immunology
FEB 27, 2019
Anti-Inflammatory Meds without Side Effects, Please
Drugs such as ibuprofen or aspirin that relieve pain and lower fever are among the most frequently used drugs worldwide....
MAR 20, 2019
Drug Discovery
MAR 20, 2019
First Drug for Postpartum Depression
The U.S. Food and Drug Administration recently approved the first ever drug specifically for the treatment of postpartum depression a common and often deva...
MAR 31, 2019
Drug Discovery
MAR 31, 2019
Glowing Tumors Reveal How Immunotherapeutics Work
In a study published in the Journal of Clinical Investigation, researchers used positron emission tomography (PET) scans to examine how an immunotherapy dr...
Loading Comments...